Proliferation of sphere‑forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine

Tomizawa,Minoru; Shinozaki,Fuminobu; Motoyoshi,Yasufumi; Sugiyama,Takao; Yamamoto,Shigenori; Ishige,Naoki

doi:10.3892/ol.2017.5565

Proliferation of sphere‑forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine

Authors:
- Minoru Tomizawa
- Fuminobu Shinozaki
- Yasufumi Motoyoshi
- Takao Sugiyama
- Shigenori Yamamoto
- Naoki Ishige
View Affiliations

Affiliations: Department of Gastroenterology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Radiology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Neurology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Pediatrics, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan, Department of Neurosurgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284‑0003, Japan
Published online on: January 2, 2017 https://doi.org/10.3892/ol.2017.5565
Pages: 1264-1268

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resistance to sorafenib in hepatocellular carcinoma (HCC) cells exhibiting stemness was evaluated using a sphere formation assay. A hepatocyte selection medium (HSM) deficient in glucose and arginine was used to suppress the proliferation of cell spheres composed of HLF and PLC/PRF/5 HCC cells, which were subjected to a sphere formation assay. Cell spheres were cultured with sorafenib and subjected to a cell proliferation assay and the expression levels of cytochrome P450 (CYP3A4) were analyzed in RNA extracted from sphere‑forming cells using reverse transcription‑quantitative polymerase chain reaction. Sphere‑forming PLC/PRF/5 cells were more resistant to sorafenib, as compared with control cells, exhibiting higher expression levels of CYP3A4. When cultured in HSM, suppressed proliferation was observed in the sphere‑forming PLC/PRF/5 cells and in the control cells, with no significant variation between them. The results suggest that deprivation of glucose and arginine is a potential novel treatment for HCC.

View Figures

View References

1	Trojan J, Zangos S and Schnitzbauer AA: Diagnostics and treatment of hepatocellular carcinoma in 2016: Standards and developments. Visc Med. 32:116–120. 2016.PubMed/NCBI
2	Lencioni R, Petruzzi P and Crocetti L: Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 30:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kim HY and Park JW: Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: Past, present, and future. Liver Cancer. 3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
4	Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 99:159–165. 2008.PubMed/NCBI
5	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
6	Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
7	Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media. Exp Ther Med. 1:863–866. 2010. View Article : Google Scholar : PubMed/NCBI
8	Okuyama H, Ikeda M, Kuwahara A, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Senda S and Okusaka T: Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib. Oncology. 88:241–246. 2015. View Article : Google Scholar : PubMed/NCBI
9	Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ye L, Yang X, Guo E, Chen W, Lu L, Wang Y, Peng X, Yan T, Zhou F and Liu Z: Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient. PLoS One. 9:e966642014. View Article : Google Scholar : PubMed/NCBI
11	Vaitheesvaran B, Xu J, Yee J, Q-Y L, Go VL, Xiao GG and Lee WN: The Warburg effect: A balance of flux analysis. Metabolomics. 11:787–796. 2015. View Article : Google Scholar : PubMed/NCBI
12	Leffert HL and Paul D: Studies on primary cultures of differentiated fetal liver cells. J Cell Biol. 52:559–568. 1972. View Article : Google Scholar : PubMed/NCBI
13	Matsumoto K, Yamada K, Kohmura E, Kinoshita A and Hayakawa T: Role of pyruvate in ischaemia-like conditions on cultured neurons. Neurol Res. 16:460–464. 1994. View Article : Google Scholar : PubMed/NCBI
14	Holden HM, Thoden JB, Timson DJ and Reece RJ: Galactokinase: Structure, function and role in type II galactosemia. Cell Mol Life Sci. 61:2471–2484. 2004. View Article : Google Scholar : PubMed/NCBI
15	Wheatley DN, Scott L, Lamb J and Smith S: Single amino acid (arginine) restriction: Growth and death of cultured HeLa and human diploid fibroblasts. Cell Physiol Biochem. 10:37–55. 2000. View Article : Google Scholar : PubMed/NCBI
16	Ohira RH, Dipple KM, Zhang YH and McCabe ER: Human and murine glycerol kinase: Influence of exon 18 alternative splicing on function. Biochem Biophys Res Commun. 331:239–246. 2005. View Article : Google Scholar : PubMed/NCBI
17	Ai Y, Jenkins NA, Copeland NG, Gilbert DH, Bergsma DJ and Stambolian D: Mouse galactokinase: Isolation, characterization, and location on chromosome 11. Genome Res. 5:53–59. 1995. View Article : Google Scholar : PubMed/NCBI
18	Phillips JW, Jones ME and Berry MN: Implications of the simultaneous occurrence of hepatic glycolysis from glucose and gluconeogenesis from glycerol. Eur J Biochem. 269:792–797. 2002. View Article : Google Scholar : PubMed/NCBI
19	Sumida KD, Crandall SC, Chadha PL and Qureshi T: Hepatic gluconeogenic capacity from various precursors in young versus old rats. Metabolism. 51:876–880. 2002. View Article : Google Scholar : PubMed/NCBI
20	Tomizawa M, Toyama Y, Ito C, Toshimori K, Iwase K, Takiguchi M, Saisho H and Yokosuka O: Hepatoblast-like cells enriched from mouse embryonic stem cells in medium without glucose, pyruvate, arginine, and tyrosine. Cell Tissue Res. 333:17–27. 2008. View Article : Google Scholar : PubMed/NCBI
21	Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M and Yoshida T: Survival of primary human hepatocytes and death of induced pluripotent stem cells in media lacking glucose and arginine. PLoS One. 8:e718972013. View Article : Google Scholar : PubMed/NCBI
22	Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ and Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
23	Reynolds BA and Weiss S: Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol. 175:1–13. 1996. View Article : Google Scholar : PubMed/NCBI
24	Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J, Fodstad O and Lorico A: Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res. 314:2110–2122. 2008. View Article : Google Scholar : PubMed/NCBI
25	Kim J, Jung J, Lee SJ, Lee JS and Park MJ: Cancer stem-like cells persist in established cell lines through autocrine activation of EGFR signaling. Oncol Lett. 3:607–612. 2012.PubMed/NCBI
26	Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, et al: Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 11:712011. View Article : Google Scholar : PubMed/NCBI
27	Nakamura T, Teramoto H, Tomita Y and Ichihara A: L-proline is an essential amino acid for hepatocyte growth in culture. Biochem Biophys Res Commun. 122:884–891. 1984. View Article : Google Scholar : PubMed/NCBI
28	Davies B and Fried M: The L19 ribosomal protein gene (RPL19): Gene organization, chromosomal mapping, and novel promoter region. Genomics. 25:372–380. 1995. View Article : Google Scholar : PubMed/NCBI
29	Olszewski U, Liedauer R, Ausch C, Thalhammer T and Hamilton G: Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro. Cancers (Basel). 3:1467–1479. 2011. View Article : Google Scholar : PubMed/NCBI
30	Pang RW and Poon RT: Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. Curr Cancer Drug Targets. 12:1081–1094. 2012. View Article : Google Scholar : PubMed/NCBI
31	Simons AL, Mattson DM, Dornfeld K and Spitz DR: Glucose deprivation-induced metabolic oxidative stress and cancer therapy. J Cancer Res Ther. 5:(Suppl 1). S2–S6. 2009. View Article : Google Scholar : PubMed/NCBI
32	Zhang D, Li J, Wang F, Hu J, Wang S and Sun Y: 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 355:176–183. 2014. View Article : Google Scholar : PubMed/NCBI
33	Phillips MM, Sheaff MT and Szlosarek PW: Targeting arginine-dependent cancers with arginine-degrading enzymes: Opportunities and challenges. Cancer Res Treat. 45:251–262. 2013. View Article : Google Scholar : PubMed/NCBI